mir-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling

Genes and Cancer

Volumn 5, Issue 9-10, 2014, Pages 353-364

  Martin, Elizabeth C ^a   Krebs, Adrienne E ^a   Burks, Hope E ^a   Elliott, Steven ^a   Baddoo, Melody ^a,b   Collins Burow, Bridgette M ^a   Flemington, Erik K ^a,b   Burow, Matthew E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

Author keywords

3 UTR; Breast cancer; MAPK; MicroRNA 155; P38; RNA seq

Indexed keywords

MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTOME;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MCF 7 CELL LINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME;

EID: 84927912988     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nature reviews Cancer 2006, 6:857-866.
2. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer research 2010, 70:3119-3127.
3. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of biological chemistry 2010, 285:17869-17879.
4. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. The Journal of biological chemistry 2008, 283:31079-31086.
5. Riaz M, van Jaarsveld MT, Hollestelle A, Prager-vander Smissen WJ, Heine AA, Boersma AW, Liu J, Helmijr J, Ozturk B, Smid M, et al: miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast cancer research : BCR 2013, 15:R33.
6. Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, Fu L, Zhang L, Wang Z, Li Z: Different miRNA expression profiles between human breast cancer tumors and serum. Frontiers in genetics 2014, 5:149.
7. Singh R, Mo YY: Role of microRNAs in breast cancer. Cancer biology & therapy 2013, 14:201-212.
8. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z: miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncology letters 2012, 4:1027-1032.
9. Wang F, Zheng Z, Guo J, Ding X: Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic oncology 2010, 119:586-593.
10. Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang HT, Li X: microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma. Oncology reports 2013, 30:2111-2118.
11. Zhang C, Zhao J, Deng H: 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Molecular and cellular biochemistry 2013, 379:201-211.
12. Tam W, Ben-Yehuda D, Hayward WS: Bic, a novel gene activated by proviral insertions in avian leukosis virusinduced lymphomas, is likely to function through its noncoding RNA. Molecular and cellular biology 1997, 17:1490-1502.
13. Faraoni I, Antonetti FR, Cardone J, Bonmassar E: miR-155 gene: a typical multifunctional microRNA. Biochimica et biophysica acta 2009, 1792:497-505.
14. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM: Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7024-7029.
15. Czyzyk-Krzeska MF, Zhang X: MiR-155 at the heart of oncogenic pathways. Oncogene 2014, 33:677-678.
16. O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D: Inositol phosphatase SHIP1 is a primary target of miR-155. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7113-7118.
17. Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A, et al: Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013, 121:3126-3134.
18. Thai TH, Patterson HC, Pham DH, Kis-Toth K, Kaminski DA, Tsokos GC: Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:20194-20199.
19. Jeansonne D, Pacifici M, Lassak A, Reiss K, Russo G, Zabaleta J, Peruzzi F: Differential Effects of MicroRNAs on Glioblastoma Growth and Migration. Genes 2013, 4:46-64.
20. Marsolier J, Pineau S, Medjkane S, Perichon M, Yin Q, Flemington E, Weitzman MD, Weitzman JB: Oncomi R addiction is generated by a miR-155 feedback loop in Theileria-transformed leukocytes. PLoS pathogens 2013, 9:e1003222.
21. Fahmi A, Smart N, Punn A, Jabr R, Marber M, Heads R: p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cellular signalling 2013, 25:898-909.
22. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Current opinion in cell biology 1997, 9:180-186.
23. Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and molecular biology reviews: MMBR 2004, 68:320-344.
24. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD: ERKs: a family of proteinserine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65:663-675.
25. Kant S, Schumacher S, Singh MK, Kispert A, Kotlyarov A, Gaestel M: Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. The Journal of biological chemistry 2006, 281:35511-35519.
26. Cargnello M, Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews : MMBR 2011, 75:50-83.
27. Nishimoto S, Nishida E: MAPK signalling: ERK5 versus ERK1/2. EMBO reports 2006, 7:782-786.
28. Gilley R, March HN, Cook SJ: ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos. Cellular signalling 2009, 21:969-977.
29. Chung J, Uchida E, Grammer TC, Blenis J: STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Molecular and cellular biology 1997, 17:6508-6516.
30. Marampon F, Ciccarelli C, Zani BM: Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Molecular cancer 2006, 5:31.
31. Mebratu Y, Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell cycle 2009, 8:1168-1175.
32. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J: Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). The Journal of biological chemistry 1996, 271:17920-17926.
33. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di Padova F, Ulevitch RJ, Han J: Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta. The Journal of biological chemistry 1997, 272:30122-30128.
34. Risco A, Cuenda A: New Insights into the p38gamma and p38delta MAPK Pathways. Journal of signal transduction 2012, 2012:520289.
35. Price MA, Cruzalegui FH, Treisman R: The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. The EMBO journal 1996, 15:6552-6563.
36. Enslen H, Raingeaud J, Davis RJ: Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. The Journal of biological chemistry 1998, 273:1741-1748.
37. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ: MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Molecular and cellular biology 1996, 16:1247-1255.
38. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J, Chen G: p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. The Journal of biological chemistry 2003, 278:4831-4839.
39. Chen W, Bowden GT: Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes. Oncogene 1999, 18:7469-7476.
40. Pottier N, Maurin T, Chevalier B, Puissegur MP, Lebrigand K, Robbe-Sermesant K, Bertero T, Lino Cardenas CL, Courcot E, Rios G, et al: Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PloS one 2009, 4:e6718.
41. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J: MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelialmesenchymal transition, invasion and metastasis in breast cancer. Oncogene 2013, 32:5614-5624.
42. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB: Proliferating cells express mRNAs with shortened 3’ untranslated regions and fewer microRNA target sites. Science 2008, 320:1643-1647.
43. Akman BH, Can T, Erson-Bensan AE: Estrogen-induced upregulation and 3’-UTR shortening of CDC6. Nucleic acids research 2012, 40:10679-10688.
44. Xu G, Fewell C, Taylor C, Deng N, Hedges D, Wang X, Zhang K, Lacey M, Zhang H, Yin Q, et al: Transcriptome and targetome analysis in MIR155 expressing cells using RNA-seq. Rna 2010, 16:1610-1622.
45. Elkon R, Drost J, van Haaften G, Jenal M, Schrier M, Oude Vrielink JA, Agami R: E2F mediates enhanced alternative polyadenylation in proliferation. Genome biology 2012, 13:R59.
46. Mayr C, Bartel DP: Widespread shortening of 3’UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009, 138:673-684.
47. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell 2012, 149:1635-1646.
48. Zhang CM, Zhao J, Deng HY: MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. Journal of biomedical science 2013, 20:79.
49. Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, Pan X, Zhang L, Yan H: Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PloS one 2012, 7:e46551.
50. Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington EK: MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virusregulated gene expression pathways. Journal of virology 2008, 82:5295-5306.
51. Trapnell C, Pachter L, Salzberg SL: TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25:1105-1111.
52. Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Molecular Cancer, in press